Axsome Therapeutics, Inc.
AXSM
Rank in Stocks
#2411
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Share Price
$155.13
Last synced: 2026-10-19
Market Cap
$8.13B
Change (1 day)
-1.28%
Change (1 year)
17.88%
Country
US
Trade Axsome Therapeutics, Inc. (AXSM)
Category
Healthcare
P/B ratio for Axsome Therapeutics, Inc. (AXSM)
P/B ratio as of October 2026 TTM: 100.29
According to Axsome Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 100.29. At the end of 2023 the company had a P/B ratio of 18.93.
P/B ratio history for Axsome Therapeutics, Inc. from 2013 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 100.29 | 41.05% |
| 2024 | 71.10 | 275.60% |
| 2023 | 18.93 | -33.86% |
| 2022 | 28.62 | -924.10% |
| 2021 | -3.47 | -68.06% |
| 2020 | -10.87 | -45.61% |
| 2019 | -19.99 | 2,736.01% |
| 2018 | -0.70 | -57.65% |
| 2017 | -1.66 | -38.65% |
| 2016 | -2.71 | -53.96% |
| 2015 | -5.89 | -83.02% |
| 2014 | -34.71 | 2.95% |
| 2013 | -33.71 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -93.77% |
US
|
|
| 13.2547 | -86.78% |
US
|
|
| 4.208 | -95.80% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -93.84% |
NL
|
